Friday, July 10, 2026

Drug profile · INN

ceftobiprole

ceftobiprole (ZEFTERA (PREVIOUSLY ZEVTERA)) is a bacterial penicillin-binding protein inhibitor.

EMA: refused Antiinfectives for systemic use (J01) J01DI01
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — ceftobiprole
Class
Antiinfectives for systemic use (J01)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

ceftobiprole (ZEFTERA (PREVIOUSLY ZEVTERA)) is a bacterial penicillin-binding protein inhibitor.

Key facts

INN ceftobiprole
Brand ZEFTERA (PREVIOUSLY ZEVTERA)
Mechanism Bacterial penicillin-binding protein inhibitor
Target Bacterial penicillin-binding protein
Therapeutic class Antiinfectives for systemic use (J01)
ATC code J01DI01

Mechanism of action

Bacterial penicillin-binding protein inhibitor

Primary target: Bacterial penicillin-binding protein

Approval history

Authority Status Date
EMA refused

Pipeline programs

  1. Ceftobiprole OATP1B interaction study Phase 1 · Anaxis Pharma · Community-acquired bacterial pneumonia

Related & competitor drugs

  1. amoxicillin Bacterial penicillin-binding protein inhibitor
  2. ampicillin sodium Bacterial penicillin-binding protein inhibitor
  3. ampicillin/ampicillin trihydrate Bacterial penicillin-binding protein inhibitor
  4. atazanavir sulfate Antiinfectives for systemic use (J05)
  5. cefaclor Bacterial penicillin-binding protein inhibitor
  6. cefadroxil/cefadroxil hemihydrate Bacterial penicillin-binding protein inhibitor

Frequently asked questions

What is ceftobiprole?

ceftobiprole (ZEFTERA (PREVIOUSLY ZEVTERA)) is a bacterial penicillin-binding protein inhibitor.

What is the brand name for ceftobiprole?

ZEFTERA (PREVIOUSLY ZEVTERA) is a marketed brand name for ceftobiprole. Check FDA Drugs@FDA for the current US label holder and prescribing information.